Swedish Orphan Biovitrum AB: Late-breaking efanesoctocog alfa data presented at ISTH demonstrates highly effective bleed protection in children with severe haemophilia A with once-weekly dosing

Pivotal data from the Phase 3 XTEND-Kids study evaluating efanesoctocog alfa [Antihemophilic Factor, Fc-VWF-XTEN Fusion Protein] once-weekly prophylaxis in previously treated patients younger than 12 years of age with severe haemophilia A were presented in a late-breaking session at the Annual Meeting of the International Society on Thrombosis and Haemostasis in Montreal, Canada.